Trevi Therapeutics logo

Trevi Therapeutics share price today

(TRVI)

Trevi Therapeutics share price is $4.32 & ₹370.70 as on 7 Jan 2025, 2.30 'hrs' IST

$4.32

-0.27

(-5.88%)

Market is closed - opens 8 PM, 07 Jan 2025

View live Trevi Therapeutics share price in Dollar and Rupees. Guide to invest in Trevi Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Trevi Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Trevi Therapeutics share price movements

  • Today's Low: $4.32
    Today's High: $4.67

    Day's Volatility :7.46%

  • 52 Weeks Low: $1.27
    52 Weeks High: $4.68

    52 Weeks Volatility :72.86%

Trevi Therapeutics Returns

PeriodTrevi Therapeutics IncIndex (Russel 2000)
3 Months
45.71%
0.0%
6 Months
71.91%
0.0%
1 Year
237.5%
0.0%
3 Years
94.49%
-19.8%

Trevi Therapeutics Key Statistics

in dollars & INR

Previous Close
$4.59
Open
$4.64
Today's High
$4.668
Today's Low
$4.32
Market Capitalization
$368.2M
Today's Volume
$572.9K
52 Week High
$4.68
52 Week Low
$1.27
Revenue TTM
$0.0
EBITDA
$-48.1M
Earnings Per Share (EPS)
$-0.44
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-59.65%

How to invest in Trevi Therapeutics from India?

It is very easy for Indian residents to invest directly in Trevi Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Trevi Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Trevi Therapeutics or TRVI on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Trevi Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Trevi Therapeutics shares which would translate to 0.199 fractional shares of Trevi Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Trevi Therapeutics, in just a few clicks!

Returns in Trevi Therapeutics for Indian investors in Rupees

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Trevi Therapeutics investment value today

Current value as on today

₹3,20,870

Returns

₹2,20,870

(+220.87%)

Returns from Trevi Therapeutics Stock

₹2,17,647 (+217.65%)

Dollar Returns

₹3,223 (+3.22%)

Indian investors sentiment towards Trevi Therapeutics

6500.0%

Period: Oct 8, 2024 to Jan 6, 2025. Change in 30 Days versus previous period

Investment in Trevi Therapeutics from India has grown in the last 30 days as on Jan 7, 2025. 6500.0% more purchase transactions for Trevi Therapeutics in the last 30 days versus the previous period.

86%

Period: Oct 8, 2024 to Jan 6, 2025. Change in 30 Days versus previous period

Search volume for Trevi Therapeutics on INDmoney from India has grown in the last 30 days as on Jan 7, 2025. 86% more investors are searching Trevi Therapeutics in the last 30 days versus the previous period.

Global Institutional Holdings in Trevi Therapeutics

  • NEA Management Company, LLC

    14.79%

  • Rubric Capital Management LP

    6.54%

  • Viking Global Investors LP

    5.72%

  • VR Adviser, LLC

    4.45%

  • Vanguard Group Inc

    4.24%

  • BlackRock Inc

    4.08%

Analyst Recommendation on Trevi Therapeutics

Buy

    91%Buy

    8%Hold

    0%Sell

Based on 12 Wall street analysts offering stock ratings for Trevi Therapeutics(by analysts ranked 0 to 5 stars)

Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
1
1
1
Sell
0
0
0

Analyst Forecast on Trevi Therapeutics

What analysts predicted

Upside of 127.14%

Current:

$4.32

Target:

$9.81

Insights on Trevi Therapeutics

  • Price Movement

    In the last 7 days, TRVI stock has moved up by 12.0%

Trevi Therapeutics Technicals Summary

Sell

Neutral

Buy

Trevi Therapeutics is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Trevi Therapeutics Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Trevi Therapeutics Inc
72.56%
71.91%
237.5%
94.49%
94.49%
Regeneron Pharmaceuticals, Inc.
-8.86%
-31.87%
-20.46%
15.59%
87.28%
Biontech Se
-4.16%
43.82%
3.49%
-49.66%
167.6%
Alnylam Pharmaceuticals, Inc.
-8.45%
-8.03%
19.03%
56.02%
98.44%
Vertex Pharmaceuticals Incorporated
-14.11%
-16.23%
-2.87%
81.78%
76.8%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Trevi Therapeutics Inc
NA
NA
NA
-0.48
-0.6
-0.37
NA
0.78
Regeneron Pharmaceuticals, Inc.
17.61
17.61
1.06
45.07
0.17
0.07
NA
272.04
Biontech Se
160.8
NA
0.04
-3.11
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.19
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
32.84
NA
1.06
0.51
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Trevi Therapeutics Inc
Buy
$368.2M
94.49%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Buy
$78.3B
87.28%
17.61
33.61%
Biontech Se
Buy
$27.3B
167.6%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Buy
$30.4B
98.44%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Buy
$103.7B
76.8%
32.84
-4.51%

About Trevi Therapeutics

trevi therapeutics, inc. is a late-stage biopharmaceutical company focused on developing nalbuphine® er for chronic pruritic conditions. pruritus develops in various dermatologic, metabolic, hematologic and neuropathic conditions. the company is pursuing several pruritic conditions for clinical development, including its lead indication of prurigo nodularis. prurigo nodularis is a chronic pruritic dermatologic condition characterized by the presence of pruriginous lesions (excoriative/ulcerative papules and nodules) on the skin. there are no approved therapies in the us or eu for this condition. nalbuphine® er is an oral extended release synthetic opioid with a dual mechanism of action, mu receptor antagonist and kappa receptor agonist, both of which have been shown in research to be effective in abolishing itch. because of nalbuphine® er’s unique dual mechanism of action, which has shown efficacy in addressing pruritus in human clinical trials, the company believes nalbuphine® er can
Organization
Trevi Therapeutics
Employees
27
CEO
Ms. Jennifer L. Good
Industry
Pharmaceuticals: Major

Management People of Trevi Therapeutics

NameTitle
Ms. Jennifer L. Good
Co-Founder, CEO, President & Director
Dr. Thomas R. Sciascia M.D.
Co-Founder & Chief Scientific Officer
Dr. James V. Cassella Ph.D.
Chief Development Officer
Ms. Lisa Delfini
Chief Financial Officer
Mr. Christopher Galletta
Controller & Chief Accounting Officer
Katie McManus
Communications Manager
Mr. Farrell Simon Pharm.D.
Chief Commercial Officer
Ms. Danine Summers
Vice President of Medical Affairs

Important FAQs about investing in Trevi Therapeutics from India :

What is Trevi Therapeutics share price today?

Trevi Therapeutics share price today stands at $4.32, Open: $4.64 ; Previous Close: $4.59 ; High: $4.67 ; Low: $4.32 ; 52 Week High: $4.68 ; 52 Week Low: $1.27. The stock opens at $4.64, after a previous close of $4.59. The stock reached a daily high of $4.67 and a low of $4.32, with a 52-week high of $4.68 and a 52-week low of $1.27.

Can Indians buy Trevi Therapeutics shares?

Yes, Indians can invest in the Trevi Therapeutics (TRVI) from India.

With INDmoney, you can buy Trevi Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Trevi Therapeutics at zero transaction cost.

How can I buy Trevi Therapeutics shares from India?

It is very easy to buy Trevi Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Trevi Therapeutics be purchased?

Yes, you can buy fractional shares of Trevi Therapeutics with INDmoney app.

What are the documents required to start investing in Trevi Therapeutics stocks?

To start investing in Trevi Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Trevi Therapeutics

Today’s highest price of Trevi Therapeutics (TRVI) is $4.67.

Today’s lowest price of Trevi Therapeutics (TRVI) is $4.32.

What is today's market capitalisation of Trevi Therapeutics

Today's market capitalisation of Trevi Therapeutics TRVI is 368.2M

What is the 52 Week High and Low Range of Trevi Therapeutics

  • 52 Week High

    $4.68

  • 52 Week Low

    $1.27

What are the historical returns of Trevi Therapeutics?

  • 1 Month Returns

    72.56%

  • 3 Months Returns

    71.91%

  • 1 Year Returns

    237.5%

  • 5 Years Returns

    94.49%

Who is the Chief Executive Officer (CEO) of Trevi Therapeutics

Ms. Jennifer L. Good is the current Chief Executive Officer (CEO) of Trevi Therapeutics.